HRP20180061T1 - Indolkarbonitrili kao selektivni modulatori androgenskih receptora - Google Patents
Indolkarbonitrili kao selektivni modulatori androgenskih receptora Download PDFInfo
- Publication number
- HRP20180061T1 HRP20180061T1 HRP20180061TT HRP20180061T HRP20180061T1 HR P20180061 T1 HRP20180061 T1 HR P20180061T1 HR P20180061T T HRP20180061T T HR P20180061TT HR P20180061 T HRP20180061 T HR P20180061T HR P20180061 T1 HRP20180061 T1 HR P20180061T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- compound according
- muscle wasting
- compound
- wasting associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672455P | 2012-07-17 | 2012-07-17 | |
| US201361748874P | 2013-01-04 | 2013-01-04 | |
| EP13758975.0A EP2875013B1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
| PCT/IB2013/001530 WO2014013309A1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180061T1 true HRP20180061T1 (hr) | 2018-02-23 |
Family
ID=49117887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180061TT HRP20180061T1 (hr) | 2012-07-17 | 2013-07-15 | Indolkarbonitrili kao selektivni modulatori androgenskih receptora |
Country Status (39)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
| KR102127939B1 (ko) * | 2012-07-17 | 2020-06-29 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴 |
| EP3097077A1 (en) * | 2014-01-21 | 2016-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
| MX2017004819A (es) * | 2014-10-16 | 2018-06-12 | Gtx Inc | Metodos de tratamiento de transtornos urológicos usando sarm. |
| CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
| CN110437125B (zh) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | 一种Tezacaftor中间体II的制备方法 |
| WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| CN115010574B (zh) * | 2022-06-06 | 2024-01-05 | 爱斯特（成都）生物制药股份有限公司 | 1-溴-2-氯-4-氟-2碘苯的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200000486A (et) | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal |
| BR9911365A (pt) * | 1998-06-19 | 2001-03-13 | Pfizer Prod Inc | Compostos pirrolo[2,3-d]pirimidina |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| ES2471240T3 (es) | 2002-05-24 | 2014-06-25 | Bayer Cropscience Ag | Procedimiento de preparación de derivados de tioalquilamina |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| CN1960973A (zh) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物 |
| CN1980917B (zh) | 2004-05-03 | 2014-02-12 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物 |
| CN1980891B (zh) | 2004-05-03 | 2011-03-09 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物 |
| US7427682B2 (en) | 2004-05-03 | 2008-09-23 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
| ES2340180T3 (es) * | 2004-06-01 | 2010-05-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas. |
| BRPI0613876A2 (pt) * | 2005-07-29 | 2011-02-15 | Pfizer Prod Inc | derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
| CN101426778A (zh) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | 作为组胺-3拮抗剂的n-经取代-氮杂环基胺 |
| ES2452343T3 (es) * | 2006-09-29 | 2014-04-01 | Glaxosmithkline Llc | Compuestos de indol sustituidos |
| JP4884570B2 (ja) * | 2008-08-20 | 2012-02-29 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| CA2776028C (en) * | 2009-10-15 | 2015-12-01 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| ES2461967T3 (es) * | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| RU2598842C2 (ru) * | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| KR102032934B1 (ko) * | 2011-12-21 | 2019-10-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도 |
| KR102127939B1 (ko) * | 2012-07-17 | 2020-06-29 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴 |
| EP3097077A1 (en) * | 2014-01-21 | 2016-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
-
2013
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/ko active Active
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/es active IP Right Grant
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/ja active Active
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/es active Active
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 RS RS20180119A patent/RS56810B1/sr unknown
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/hu unknown
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 EA EA201492237A patent/EA026371B8/ru not_active IP Right Cessation
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 MX MX2015000825A patent/MX349943B/es active IP Right Grant
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/lt unknown
- 2013-07-15 TW TW102125297A patent/TWI574946B/zh active
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 PT PT137589750T patent/PT2875013T/pt unknown
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/pt active IP Right Grant
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 PL PL13758975T patent/PL2875013T3/pl unknown
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 AR ARP130102513A patent/AR091770A1/es active IP Right Grant
- 2013-07-15 UY UY0001034911A patent/UY34911A/es not_active Application Discontinuation
- 2013-07-15 HR HRP20180061TT patent/HRP20180061T1/hr unknown
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/zh active Active
- 2013-07-15 SM SM20180115T patent/SMT201800115T1/it unknown
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/me unknown
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/ar active
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en not_active Ceased
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/es unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/es unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/es unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104B1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/es unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/el unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180061T1 (hr) | Indolkarbonitrili kao selektivni modulatori androgenskih receptora | |
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| JP2015522603A5 (https=) | ||
| MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| JP2015524444A5 (https=) | ||
| MD4539B1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2009541348A5 (https=) | ||
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| JP2015038135A5 (https=) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| EA201100814A1 (ru) | Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик | |
| JP2013231087A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| WO2017037593A3 (zh) | 用于减少局部脂肪的医药组成物及其用途 | |
| WO2008084504A3 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
| WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
| HRP20250615T1 (hr) | Tradipitant za upotrebu u liječenju gastropareze | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| WO2013026558A3 (de) | Kombinationstherapeutikum | |
| MY151230A (en) | Novel method |